In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenance ...

December 5, 2010 (Orlando, Florida) — Patients with asymptomatic nonbulky follicular lymphoma are generally followed with a "wait and watch" approach and then treated with chemotherapy as and ...

Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m 2).

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

Strati led a study that evaluated acalabrutinib alone or in combination with rituximab for follicular lymphoma. In treatment-naive patients, the combination led to an ORR of 92% and CR rate of 39%.

In the subsequent phase III CHRONOS-3 trial, adding copanlisib to rituximab improved PFS over rituximab alone in relapsed indolent non-Hodgkin's lymphoma, including patients with follicular lymphoma.

With lower toxicity and equal efficacy, radioimmunotherapy is a better option than autologous stem cell transplant (ASCT) for relapsed /refractory follicular lymphoma consolidation, new data show ...

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data ...

For patients with relapsed or refractory follicular lymphoma, Monjuvi (tafasitamab-cxix) in addition to Revlimid (lenalidomide) and Rituxan (rituximab) led to a 57% reduction in the risk of disease ...

Sehn LH, Luminari S, Scholz CW, et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND). Blood. 2024;144(2):LBA-1 ...

The FDA has approved Monjuvi (tafasitamab-cxix), a CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma.